Preface: Real-World Clinical Experience with Alefacept—The Amevive Wisdom Acquired from Real-World Evidence (AWARE) Study

Guenther L Langley RG Shear NH . Integrating biologic agents into management of moderate-to-severe psoriasis: A consensus of the Canadian Psoriasis Expert Panel. J Cutan Med Surg 2004;8:321–37.

Hong J Koo B Koo J . The psychosocial and occupational impact of chronic skin disease. Dermatol Ther 2008;21:54–9.

Debertret L Mrowietz U Ranki A . European patient perspectives on the impact of psoriasis: The EUROPSO patient membership survey. Br J Dermatol 2006;155:729–36.

Krueger G Koo J Lebwohl M . The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001;137:280–4.

National Psoriasis Foundation. National Psoriasis Foundation 2008 survey panel snapshot. Available at http://psoriasis.org/files/pdfs/research/2008_fall_survey_panel.pdf (accessed November 8, 2008).

Boehncke WH Prinz J Gottlieb AB . Biologic therapies for psoriasis. A systematic review. J Rheumatol 2006;33:1447–51.

Lui H Langley R Poulin Y . Incorporating biologics into the treatment of psoriasis. J Cutan Med Surg 2004;8 Suppl:8-–13.

van Duijnhoven MH de Jong EM Gerritsen WJ . Alefacept modifies long-term disease severity and improves the response to other treatments. Eur J Dermatol 2005;15:366–73.

Sterry W Barker J Boehncke W-H . Biological therapies in the systemic management of psoriasis: International consensus conference. Br J Dermatol 2004;151 Suppl 69:3-–17.

Stein KR Pearce DJ Feldman SR . The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care. Semin Cutan Med Surg 2005;24:52–7.

Gordon KB Langley RG . Remittive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol 2003;2:624–8.

Astellas Pharma Canada Inc. Amevive [product monograph]. June 1, 2006.

Lebwohl M Christophers E Langley R , for the Alefacept Clinical Study Group. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003;139:719–27.

Krueger GG Papp KA Stough DB . A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002;47:821–33.

Menter A Cather JC Baker D . The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol 2006;54:61–3.

Gribetz CH Blum R Brady C . An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis. J Am Acad Dermatol 2005;53:73–5.

Langley RG Gordon KB . Duration of remission of biologic agents for chronic plaque psoriasis. J Drugs Dermatol 2007;6:1205–12.

Perlmutter A Cather J Franks B . Alefacept revisited: Our 3-year clinical experience in 200 patients with chronic plaque psoriasis. J Am Acad Dermatol 2008;58:116–24.

Goffe B Papp K Gratton K . An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin Ther 2005;27:1912–21.

Bio-Trends Research Group. Dermatologists report increased use of biologics in the treatment of psoriasis. June 5, 2008. Available at http://www.bio-trends.com (accessed December 5, 2008).

Gottlieb AB Casale TB Frankel E . CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: Results of a randomized study. J Am Acad Dermatol 2003;49:816–25.

Lebwohl M Bagel J Gelfand JM . From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol 2008;58:94–105.

Fomin I Caspi D Levy V . Vaccination against influenza in rheumatoid arthritis: The effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis 2006;65:191–4.

Kaine JL Kivitz AJ Birbara C Luo AY . Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 2007;34:272–9.

Visvanathan S Keenan GF Baker DG . Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone. J Rheumatol 2007;56:3096–106.

Kapetanovic MD Saxne T Nilsson JA Geborek P . Influenza vaccination as a model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology 2007;46:608–11.

Rico MJ Krell JM Bagel J Coynik DJ . Assessment and Tracking of Long-Term Alefacept Safety (ATLAS): analysis of data from approximately 1200 patients. Poster presented at the 21st World Congress of Dermatology; 2007 September 30–October 5; Buenos Aires, Argentina.

Krueger GG Gottlieb AB Sterry W . A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis. J Dermatolog Treat 2008;19:146–55.

Ortonne J-P Kemis A Koo JYM Choi J . An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2005;19:556–63.

Ortonne J-P Kemis A Koo JYM Choi J . An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2005;19:556–63.